rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2012-8-5-691-693rpcardio-584Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯLIPID-LOWERING EFFICACY OF ROSUVASTATIN COMPARED WITH OTHER STATINSГИПОЛИПИДЕМИЧЕСКАЯ ЭФФЕКТИВНОСТЬ РОЗУВАСТАТИНА В СРАВНЕНИИ С ДРУГИМИ СТАТИНАМИМешковА. Н.MeshkovA. N.

к.м.н., руководитель лаборатории молекулярной генетики

meshkov@cardio.ruГосударственный научно-исследовательский центр профилактической медициныРоссияState Research Center for Preventive MedicineRussian Federation20120601201685691693Copyright © Meshkov A.N., 20152015Мешков А.Н.Meshkov A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/584

Assessment of lipid-lowering effect of rosuvastatin is presented, as well as the main results of the study of rosuvastatin therapy efficacy , in comparison with other statins, received in controlled clinical trials of the GALAXY program: COMETS, LUNAR, MERCURY-I, SOLAR, STELLAR.

Дана оценка гиполипидемического действия розувастатина и представлены основные результаты изучения эффективности терапии розувастатином в сравнении с другими статинами, полученные в контролируемых клинических исследованиях, таких как COMETS, LUNAR, MERCURY-I, SOLAR, STELLAR, входящих в программу GALAXY .

статинырозувастатинрандомизированные контролируемые исследованияstatinsrosuvastatinrandomized controlled studyReferencesKannel W.B. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62: 1109–1112.Kannel W.B. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62: 1109–1112.Wilson P .W.F ., D’Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–47.Wilson P .W.F ., D’Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837–47.Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.Sacks F .M., Pfeffer M.A., Moyи L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 336: 1001–1009.Sacks F .M., Pfeffer M.A., Moyи L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 336: 1001–1009.Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615–1622.Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615–1622.Combating major diseases in Europe — current problems and their solutions WHO Fact Sheet WHO EURO / 03/06. Available at: http://www.med.by/who/2006/fs0306r .pdf. Date of access: 10/10/2012. Russian (Борьба с основными болезнями в Европе – актуальные проблемы и пути их решения ВОЗ, Факты и цифры ЕРБ ВОЗ/03/06. Доступно на: http://www.med.by/who/2006/fs0306r .pdf. Дата доступа: 10/10/2012).Combating major diseases in Europe — current problems and their solutions WHO Fact Sheet WHO EURO / 03/06. Available at: http://www.med.by/who/2006/fs0306r .pdf. Date of access: 10/10/2012. Russian (Борьба с основными болезнями в Европе – актуальные проблемы и пути их решения ВОЗ, Факты и цифры ЕРБ ВОЗ/03/06. Доступно на: http://www.med.by/who/2006/fs0306r .pdf. Дата доступа: 10/10/2012).Kharchenko V.I., Kakorina E.P ., Koryakin M.V. et al. Mortality from cardiovascular diseases in Russia and developed countries. The need to strengthen cardiac services and modernization of medical statistics in the Russian Federation. Rossiyskiy Kardiologicheskiy Zhurnal 2005; (2): 3–9.Харченко В.И., Какорина Е.П., Корякин М.В. и соавт. Смертность от болезней системы кровообращения в России и экономически развитых странах. Необходимость усиления кардиологической службы и модернизации медицинской статистики в Российской Федерации. Российский Кардиологический Журнал 2005; (2): 3–9.Kharchenko V.I., Kakorina E.P ., Koryakin M.V. et al. Mortality from cardiovascular diseases in Russia and developed countries. The need to strengthen cardiac services and modernization of medical statistics in the Russian Federation. Rossiyskiy Kardiologicheskiy Zhurnal 2005; (2): 3–9.Харченко В.И., Какорина Е.П., Корякин М.В. и соавт. Смертность от болезней системы кровообращения в России и экономически развитых странах. Необходимость усиления кардиологической службы и модернизации медицинской статистики в Российской Федерации. Российский Кардиологический Журнал 2005; (2): 3–9.Boitsov S., Khomitskaya Y .U.V. Results of centralized pan-Russian survey on the undertreatment of hypercholesterolemia (CEPHEUS). Eur Heart J 2012; 33 (Abstract Supplement): 451.Boitsov S., Khomitskaya Y .U.V. Results of centralized pan-Russian survey on the undertreatment of hypercholesterolemia (CEPHEUS). Eur Heart J 2012; 33 (Abstract Supplement): 451.Oganov R.G., Kukharchuk V.V., Arutyunov G.P .et al The continuing violations of lipid profile in patients with dyslipidemia treated with statins in clinical practice in the Russian Federation (the Russian part of the study DYSIS). Kardiovaskulyarnaya Terapiya i Profilaktika 2012; 11(4) 99–108. Russian (Оганов Р .Г ., Кухарчук В.В., Арутюнов Г .П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная Терапия и Профилактика 2012; 11(4) 99–108).Oganov R.G., Kukharchuk V.V., Arutyunov G.P .et al The continuing violations of lipid profile in patients with dyslipidemia treated with statins in clinical practice in the Russian Federation (the Russian part of the study DYSIS). Kardiovaskulyarnaya Terapiya i Profilaktika 2012; 11(4) 99–108. Russian (Оганов Р .Г ., Кухарчук В.В., Арутюнов Г .П. и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная Терапия и Профилактика 2012; 11(4) 99–108).Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007;5(2):177–93.Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007;5(2):177–93.Stalenhoef A.F ., Ballantyne C.M., Sarti C., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26(24):2664–72.Stalenhoef A.F ., Ballantyne C.M., Sarti C., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005;26(24):2664–72.Pitt B., Loscalzo J., Monyak J., et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012;109(9):1239–46.Pitt B., Loscalzo J., Monyak J., et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012;109(9):1239–46.Stender S., Schuster H., Barter P ., et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005;7(4):430–8.Stender S., Schuster H., Barter P ., et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005;7(4):430–8.Insull W. Jr ., Ghali J.K., Hassman D.R., et al.; SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 2007;82(5):543–50.Insull W. Jr ., Ghali J.K., Hassman D.R., et al.; SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc 2007;82(5):543–50.McKenney J.M., Jones P .H., Adamczyk M.A., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19(8):689–98.McKenney J.M., Jones P .H., Adamczyk M.A., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19(8):689–98.

The authors declare that there are no conflicts of interest present.